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of 5 FACT accredited HCTP, analyzed Medicare claims data
submitted by SCBCN between 1/1/11 and 12/31/11. 120 HCT
were performed on 119 patients (pts): 69 men and 50
women, median age 67 years (range 28-79) with Multiple
Myeloma (62), Lymphoma (35), Acute Leukemia (17) and
other (5). There were 23 allogeneic (allo) HCT (MS-DRG-14),
2 of which were outpatient with an average length of stay
(LOS) of 30 days (0-123) for related and 25 days (5-55) for
unrelated; 12/23 were < 20 days. Inpatient coding for
autologous (auto) HCT was split among three MS-DRG
because of a change in 2012 from MS-DRG- 15 (71) and to
MS-DRG 16dwith complication/comorbidity (cc) (18) and
MS-DRG 17dwithout cc (8) with average LOS 18 days (2-39);
55/97 were<20 days. Of 18 pts assigned DRG16, all appeared
to have codes supporting increased complexity. Of 8 pts
assigned DRG17, 5 had codes that might have supported
billing under DRG 16. Among 23 allo pts, 7 were missing the
code deﬁning donor source as related or unrelated including
both patients who received outpatient allo HCT. Revenue
code 819, which reports charges for donor cell acquisition,
was reported in 18 cases with a 40-fold variance in range of
charges. Interestingly, this code was also submitted in 46 of
97 auto cases.
Conclusion: Signiﬁcant opportunities may exist for using
the proper MS-DRG for auto pts (which has substantial
revenue implications) and the use of revenue code 819 for
allo HCT (which has substantial implications for future rate
setting). Programs can signiﬁcantly increase future
payment rates by understanding their current Medicare
billing practices and identifying opportunities for
improvement. Further investigation will focus on estima-
tion of costs as compared with reimbursement for Medi-
care beneﬁciaries.332
CIBMTR Data Management Training Survey 2012
Theresa M. McKay, Kathleen Ruehle. University of Maryland
Greenebaum Cancer Center, Baltimore, MD
Purpose: Effective training of data managers (DM) is
instrumental to assure accurate, quality data. The National
Marrow Donor Program (NMDP) and the Center for Inter-
national Blood and Marrow Transplant Research (CIBMTR)
network provide training resources and liaisons for each
transplant center in order to assist in proper completion of
the CIBMTR data collection forms. The University of Mary-
land Greenebaum Cancer Center's (UMGCC) Blood and
Marrow Transplant (BMT) team utilizes the CIBMTR elec-
tronic training resources and liaisons, as well as other alter-
native training methods. Our team was interested in
assessing the effectiveness of DM training methods and to
enhance the CIBMTR DM training model.
Method: The UMGCC BMT team developed an anonymous,
twenty-question survey on the various training methods
implemented at 138 NMDP and CIBMTR-afﬁliated transplant
centers in the U.S. The survey consisted of quantitative and
qualitative questions pertaining to demographics, prior DM
experience, and training.
Results: Seventy DMs responded to the survey. Participant
ages were well distributed with 29% of participants 18 to 34
years, 39% 35 to 49 years, and 33 % 50 to 64 years. Most
respondents (66%) reported that they had been a CIBMTR DM
for greater than 5 years. Half (51%) participated in monthly
internal assessments and 57% worked at centers thatperformed over 100 transplants per year. When asked about
training to become a DM, 51% reported having less than 1
week of training and 88% reported not being extremely
satisﬁed with his/her DM training. Thirty percent had no
previous experience with BMT-related information when
they became a DM and most (53%) were not audited prior to
independently completing CIBMTR forms. Training to
complete CIBMTR forms ranged from none to training
received from multiple sources. At the time of the survey,
54% were not familiar with the current CIBMTR training
model.
Conclusion: The CIBMTR DM Training Methods Survey
shows that CIBMTR DMs vary by age, previous experience,
and levels of training. Based on the data, it is evident that
a trainingmodel, which incorporates speciﬁc procedures and
methods, would be of value to CIBMTR DMs and the data
they report. Standardized DM training would improve the
accuracy and quality of data, which would contribute to the
knowledge learned from hematopoietic stem cell transplant
research.333
Standardizing Standard Operating Procedures' (SOP)
Manual to Benchmark Cell Processing Laboratory (CPL)
Performance
Mehboob Merchant 1, Morris Kletzel 1,2,3, Marcelo Villa 1,
Thomas Shook 1, Leo I. Gordon 1,4. 1 Cell Therapy Processing
Facility, Northwestern Memorial Hospital, Chicago, IL;
2 Northwestern University Feinberg School of Medicine,
Chicago, IL; 3 Ann & Robert H. Lurie Children's Hospital of
Chicago; 4 Northwestern Univ Medical School, Div of Hem/Onc,
Chicago, IL
Background: Healthcare SOPs are now standardized. There
are a few hundred routine CPL policies/procedures (P/P) and
maintaining SOP Manual (SOPM) becomes a daunting task.
SOP of any two labs would not only differ on how to achieve
the same task but no two SOPM would equally cover all
topics required by regulatory and/or accrediting agency
(R/AA).
Amongst the R/AA, JC, OSHA, CLIA, CAP, AABB, FACT & FDA
all have oversight claims on the lab, including lab practices
and SOPs. Failure to abide may result in catastrophic
outcome from citation to shut down and insurance
disapproval.
Objective: R/AA have common minimum standards-
patient safety is the prime concern, and it may be possible
to standardize R/AA requirements so that SOPM for every
CPL is identical in content, achieving uniformity across the
board.
Methods: In 2008, our CPL had a management change
and became an independent lab with a cGMP facility. We
inherited SOPs from two departments, a total of 161
policies plus 204 forms. There was confusion and dupli-
cation with two dissimilar SOPs and formats, also
previous P/P had not been updated to current regulatory
guidelines.
Early in 2010, we merged the two sets into integrated,
practical and regulatory-compliant documents with novel
formatting to distinguish one from the others. FDA regula-
tions took precedence over other R/AA.
FDA, FACT, CAP and the JC's guidelines were keenly
scrutinized prior to addressing the merger. SOPs were sorted
into three broad categories: Quality Management, Cell Pro-
cessing and cGMP.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S257eS278 S277Result: During the course of this merger, we concluded that
only one cGMP policy was required since GMP users had
their own program SOP. However, GMP users would be
trained in QM policies besides their own P/P. Our current
SOPM has 70 P/P, 81 forms & 3 presentations, covering all
areas of processing and is compliant with R/AA.
Conclusion: Our rationale for standardizing SOPM is based
speciﬁcally on 21 CFR Part 1271 which governs all CPLs and is
mandatory law. With standardization, we will have clarity,
identical training for staff, and assurance of adherence to
similar methodology as required by law, resulting in
consistency, uniformity, legitimacy and safety in our labo-
ratory manufactured products.P/P Title Sub Titles Forms
I. Q M
1. Quality Assurance Organization; Terminology
2. Good Manufacturing
3. Responsibilities Lab Tech to MD
4. Security & Safety Safety manual etc 2
5. Utility Mgmt Air Handling; Compressor; etc 12
6. Training Training; Competency; CE 2
7. S.O.P. Mgmt Writing; Controls 5
8. Systems Controls; Validation 5
9. Event Mgmt 2
10. Audit 1
11. Equipment Mgmt BSC; Incubator etc; PM etc 7
12. Accreditation Mgmt 5
13. Supplies 2
14. E M Mgmt 4
15. Cleaning, Sanitization 2
16. Data Mgmt Documentation; Billing
II. Processing
1. HCT/P Quality Assurance Donor, Patient, Product 3
2. Quality Testing 1
3. Chain of Custody 3
4. HCT/P Manufacturing From Receipt to Infusion 20
5. Data Mgmt
6. Equipment Ops Cobe 2991; Cell Counter etc 5
III. cGMP
1. Gowning334
Substantial Variation in Medicaid Coverage for
Hematopoietic Cell Transplantation
Jaime M. Preussler 1, Stephanie Farnia 2, Ellen Denzen 3,
Navneet S. Majhail 2. 1 Patient Services, Natoinal Marrow
Donor Program, Minneapolis, MN; 2National Marrow Donor
Program, Minneapolis, MN; 3 Patient Services, National
Marrow Donor Program (NMDP)
Medicaid is a jointly funded federal-state program that
provides payment for health services for pregnant women,
children, parents, seniors and disabled individuals. States
establish and administer their own Medicaid programs and
determine the type, amount, and scope of services within
federal guidelines which mandate coverage of certain
beneﬁts. Optional beneﬁts that can be provided by the state
can lead to a wide variation of beneﬁts offered. Hemato-
poietic cell transplant (HCT) is not a mandatory covered
service for adults, and each state has the discretion to
choose whether to cover it and the extent of the coverage.
Variation in state policies can impact access to care for
patients. At the same time, many patients rely on Medicaid
for HCT coverage e according to HCUPnet data, Medicaid
paid for 3,064 HCT hospitalizations (16% of HCT discharges)
in the US in 2010. A national comparison of Medicaid
coverage for HCT was undertaken to learn more about statevariation. Information on HCT coverage beneﬁts for 2012
was collected from state Medicaid websites and was
compared to the recommendations for minimum beneﬁts
that have been developed by the National Marrow Donor
Program in collaboration with physicians, transplant
centers and payors (www.marrow.org/payor). Data was
coded on a three point scale depending on whether indi-
vidual state coverage met minimum beneﬁts criteria (score
2), provided some but not minimum beneﬁts (score 1), or
did not provide any beneﬁts (score 0) for the following 5
categories: 1) transplant procedure and disease indications,
2) donor search, 3) medications, 4) clinical trials, and 5)
patient food, lodging and transportation. Data were avail-
able for 47 states (Figure 1). No state provided minimum
coverage beneﬁts in all 5 categories and only three states
met the minimum in 4/5 categories. Our study highlights
substantial variation in Medicaid coverage by state for HCT
which may serve as a barrier to access to HCT for some
patients. In light of the Affordable Care Act and the deter-
mination of Essential Beneﬁts by individual states,
a common framework for complex medical procedures
such as HCT may be beneﬁcial.
Figure 1.
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The Beneﬁts of Metadata Analysis and Form Question
Harmonization
Sandra Sorensen, Robinette Renner. CIBMTR - IT, National
Marrow Donor Program, Minneapolis, MN
Background: In order to collect high-quality data from
multiple organizations, there must be a clear understanding
as to what data is needed and how it is to be reported.
Metadata, often described as “data about data,” describes
the content, quality, and other attributes of the data being
collected. These attributes include maximum length,
number of decimal places, data type (character, number, or
date), multiple choice answer vs. free text, etc. Historically,
FormsNet (FN), the Center for International Blood and
Transplant Research's (CIBMTR) electronic data capture
system, stored the metadata at the question level. Since
data collection forms were created independently, differ-
ences in question design and metadata became problem-
atic. For example, primary disease is a list of valid values on
one form and free text on another. In an effort to improve
data quality and facilitate analysis, the use of well-deﬁned
metadata and data standards, took on a more prominent
role.
Methods: Common data elements (CDE) were created using
the National Cancer Institute's Cancer Data Standards
